Eledon Capital Stock vs Accounts Payable Analysis
ELDN Stock | USD 2.41 0.11 4.78% |
Eledon Pharmaceuticals financial indicator trend analysis is much more than just examining Eledon Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eledon Pharmaceuticals is a good investment. Please check the relationship between Eledon Pharmaceuticals Capital Stock and its Accounts Payable accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.
Capital Stock vs Accounts Payable
Capital Stock vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eledon Pharmaceuticals Capital Stock account and Accounts Payable. At this time, the significance of the direction appears to have weak relationship.
The correlation between Eledon Pharmaceuticals' Capital Stock and Accounts Payable is 0.39. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Eledon Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Eledon Pharmaceuticals' Capital Stock and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of Eledon Pharmaceuticals are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Capital Stock i.e., Eledon Pharmaceuticals' Capital Stock and Accounts Payable go up and down completely randomly.
Correlation Coefficient | 0.39 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Capital Stock
The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.Accounts Payable
An accounting item on the balance sheet that represents Eledon Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Eledon Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from Eledon Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eledon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.Eledon Pharmaceuticals reported last year Tax Provision of (579,000). As of the 3rd of May 2024, Enterprise Value is likely to grow to about 74.2 M, while Selling General Administrative is likely to drop about 12.1 K.
Eledon Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Eledon Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eledon Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 10.9M | 197.2M | 170.5M | 92.8M | 125.9M | 81.1M | |
Other Current Liab | 813K | 973K | 2.2M | 3.9M | 2.5M | 2.2M | |
Total Current Liabilities | 1.3M | 2.5M | 4.4M | 6.5M | 3.9M | 3.7M | |
Total Stockholder Equity | 9.5M | 190.6M | 164.0M | 84.2M | 83.4M | 60.7M | |
Property Plant And Equipment Net | 321K | 138K | 768K | 739K | 365K | 278.2K | |
Net Debt | (8.5M) | (114.1M) | (84.1M) | (55.7M) | (4.2M) | (4.4M) | |
Retained Earnings | (57.6M) | (80.4M) | (114.9M) | (202.9M) | (243.2M) | (231.0M) | |
Accounts Payable | 329K | 1.4M | 1.8M | 2.2M | 967K | 1.0M | |
Cash | 8.8M | 114.2M | 84.8M | 56.4M | 4.6M | 4.4M | |
Non Current Assets Total | 960K | 81.6M | 82.2M | 33.3M | 69.8M | 73.3M | |
Non Currrent Assets Other | 639K | 383K | 400K | 150K | 186K | 309.2K | |
Cash And Short Term Investments | 8.8M | 114.2M | 84.8M | 56.4M | 51.1M | 53.7M | |
Common Stock Shares Outstanding | 655.5K | 1.5M | 14.8M | 14.3M | 24.6M | 25.9M | |
Liabilities And Stockholders Equity | 10.9M | 197.2M | 170.5M | 92.8M | 125.9M | 81.1M | |
Non Current Liabilities Total | 144K | 4.1M | 2.2M | 2.1M | 38.6M | 40.5M | |
Other Current Assets | 54K | 38K | 3.5M | 3.1M | 5.0M | 5.3M | |
Other Stockholder Equity | 67.0M | 271.0M | 278.9M | 287.0M | 326.6M | 166.9M | |
Total Liab | 1.5M | 6.6M | 6.6M | 8.6M | 42.5M | 44.6M | |
Property Plant And Equipment Gross | 321K | 138K | 768K | 739K | 365K | 278.2K | |
Total Current Assets | 10.0M | 115.6M | 88.3M | 59.5M | 56.1M | 56.0M | |
Common Stock Total Equity | 7K | 9K | 13K | 15K | 13.5K | 12.8K | |
Common Stock | 9K | 13K | 15K | 14K | 24K | 13.1K | |
Net Tangible Assets | 12.6M | 9.5M | 109.6M | 83.0M | 95.4M | 100.2M | |
Property Plant Equipment | 14K | 321K | 138K | 768K | 883.2K | 927.4K | |
Net Invested Capital | 9.5M | 190.6M | 164.0M | 84.2M | 83.4M | 88.9M | |
Net Working Capital | 8.6M | 113.1M | 83.9M | 53.0M | 52.2M | 53.5M |
Pair Trading with Eledon Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eledon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eledon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Eledon Stock
0.57 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
0.51 | IPSC | Century Therapeutics Financial Report 9th of May 2024 | PairCorr |
0.46 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
0.45 | LGVN | Longeveron LLC Earnings Call This Week | PairCorr |
0.44 | TXG | 10X Genomics | PairCorr |
The ability to find closely correlated positions to Eledon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eledon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eledon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eledon Pharmaceuticals to buy it.
The correlation of Eledon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eledon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eledon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eledon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.Note that the Eledon Pharmaceuticals information on this page should be used as a complementary analysis to other Eledon Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Eledon Stock analysis
When running Eledon Pharmaceuticals' price analysis, check to measure Eledon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eledon Pharmaceuticals is operating at the current time. Most of Eledon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eledon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eledon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eledon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Eledon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Return On Assets (0.30) | Return On Equity (0.48) |
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.